Table 2 Uni- and multi-variate analysis for overall survival.

From: Significant muscle loss after stereotactic body radiotherapy predicts worse survival in patients with hepatocellular carcinoma

Variable

Univariate

Multivariate

HR (95% CI)

p

HR (95% CI)

p

Pre-SBRT sarcopenia

1.50 (1.01–2.22)

0.04

1.61 (0.99–2.61)

0.05

SMI loss ≥ 7%

3.24 (2.11–4.99)

 < 0.001

1.96 (1.15–3.33)

0.01

Age > 60

1.20 (0.80–1.79)

0.39

  

Sex male vs. female

0.94 (0.59–1.49)

0.76

  

ECOG ≥ 2

3.38 (1.90–5.99)

 < 0.001

1.59 (0.80–3.15)

0.19

AFP ≥ 200 ng/ml

1.45 (0.97–2.18)

0.07

1.44 (0.87–2.39)

0.16

ALBI (per 0.01-unit increase)

1.005 (1.002–1.009)

0.003

0.999 (0.995–1.004)

0.77

NLR ≥ 2.5

2.27 (1.47–3.49)

 < 0.001

1.79 (1.07–3.00)

0.03

Prior treatment

1.00 (0.67–1.50)

1.00

  

Multiple tumors

2.19 (1.46–3.30)

 < 0.001

2.19 (1.30–3.71)

0.003

Tumor size ≥ 5 cm

2.12 (1.42–3.16)

 < 0.001

1.57 (0.95–2.59)

0.08

Macrovascular invasion

1.92 (1.27–2.92)

0.002

1.26 (0.76–2.07)

0.37

Extrahepatic metastasis

6.65 (3.90–11.32)

 < 0.001

3.47 (1.79–6.73)

 < 0.001

BED (per 1 Gy increase)

0.985 (0.976–0.995)

0.003

0.998 (0.985–1.010)

0.69

  1. SBRT: stereotactic body radiotherapy; SMI: skeletal muscle index; ECOG: Eastern Cooperative Oncology Group; AFP: alpha fetal protein; ALBI: albumin-bilirubin; NLR: neutrophil lymphocyte ratio; BED: biological effective dose; HR: hazard ratio; CI: confidence interval.
Back to article page